Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 17, 1999

View Archived Issues

Wistar Institute discovers mechanism of action of farnesyltransferase inhibitors

Company Profile: Resolution Pharmaceuticals

Celexa approved in Canada

Medeva: year-end 1998 highlights

Alza and Sequus registration statement declared effective

Initial findings reported for CollaGenex's anticancer compound

Cerus gears up for U.S. phase III trials of platelet pathogen inactivation system

Fresenius will distribute Genzyme's Sepra products in select European markets

Sildenafil safe and effective in the treatment of ED in diabetic men

Vertex patents new series with strong and specific p38 kinase-inhibitory activity

Lilly's new orally active anticoagulants

New quinolones from Dong Wha with improved Gram-positive activity and high safety

Tachykinin antagonists in early development at Pfizer

DuPont patents novel CRF antagonists for wide range of conditions

Abbott is also recipient of Prix Galien for its protease inhibitor

S-5920 superior to methylprednisolone in protecting against ARDS

Aastrom cord blood therapy kit receives CE Mark approval

New vasopeptidase inhibitor advances in clinical trials at Bristol-Myers Squibb

Provigil tablets now available in the U.S.

PathoGenesis's CF treatment approved in Canada and Argentina

Potent, selective and orally bioavailable 5-ht6 receptor antagonist presented by SB

Early clinical results presented for ABX-IL-8 in psoriasis

Antiarthritic effects, mechanism and GI safety of S-2474 evaluated in rat model

NeoTherapeutics expands Neotrofin clinical trials internationally

FDA says KeraVision's treatment for myopia approvable

Celgene initiates Canadian clinical trial program for chirally pure form of Ritalin

Ligand introduces second new product this month

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...